Exhibit 10.16

 

DEVELOPMENT AND CLINICAL SUPPLIES AGREEMENT AMENDMENT NO. 1*

 

Radius Health Inc. (“RADIUS”) and 3M COMPANY (“3M”) and 3M INNOVATIVE PROPERTIES
COMPANY (“3M IPC”) entered into the certain Development and Clinical Supplies
Agreement (the “Agreement”) as of June 19, 2009 (“Effective Date”).

 

Pursuant to Paragraph 9.4 of the Agreement, the parties wish to enter into this
Amendment No. 1 to the Agreement (“Amendment No. 1”) effective as of
December 31, 2009 (“Amendment Date”).  Capitalized terms used in this Amendment
No. 1 and not defined herein are used with the meanings ascribed to them in the
Agreement.

 

NOW THEREFORE, in consideration of the mutual covenants and promises contained
in this Amendment No. 1, the parties agree as follows:

 

1.  Change in Work Plan; Change in Price Structure.  The parties were required
to undertake additional work not contemplated by the Work Plan concerning
viscosity experiments with respect to the Product.  This additional work
increased the costs to perform Stage 3 of the Work Plan above the Program Cost
Estimate set forth in the Agreement.  The parties have conferred with respect to
these incremental costs as well as the activities and pricing outlined in the
Work Plan and have agreed that the costs for these viscosity experiments as well
as all other activities outlined in the Work Plan, including but not limited to
preclinical and clinical activities relating to the development and
manufacturing of the [*] and [*] mcg doses, stability testing, information
supporting manufacturing and regulatory filings, as well as on site training
support for clinicians shall not exceed $[*] in the aggregate.

 

2.  Ratification.  Except to the extent expressly amended by this Amendment
No. 1, all of the terms, provisions and conditions of the Agreement are hereby
ratified and confirmed and shall remain in full force and effect.  The term
“Agreement”, as used in the Agreement, shall henceforth be deemed to be a
reference to the Agreement as amended by this Amendment No. 1.

 

3.  General.  This Amendment No. 1 may be executed in counterparts, each of
which will be deemed an original with all such counterparts together
constituting one instrument.

 

[remainder of this page intentionally left blank]

 

--------------------------------------------------------------------------------

* Confidential Treatment Requested by the Registrant. Redacted Portion Filed
Separately with the Commission.

 

1

--------------------------------------------------------------------------------

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment No. 1 to be
executed and duly delivered by their respective duly authorized officers,
intending it to take effect as of the Amendment Date.

 

3M COMPANY

 

 

 

 

 

 

 

 

 

 

 

Signed:

/s/ James A. Vaughan

 

Dated:

01/18/2010

 

 

 

 

 

Printed: James A. Vaughan

 

Title: 3M Drug Delivery System Division
Vice-President

 

 

 

 

 

 

3M INNOVATIVE PROPERTIES COMPANY

 

 

 

 

 

 

 

 

 

Signed:

/s/ Robert W. Sprague

 

Dated:

January 13, 2010

 

 

 

 

 

Printed: Robert W. Sprague

 

Title: Secretary

 

 

 

 

 

 

RADIUS HEALTH INC.

 

 

 

 

 

 

Signed:

/s/ B.N. Harvey

 

Dated:

2/24/10

 

 

 

 

 

Printed: B. Nicholas Harvey

 

Title: Chief Financial Officer

 

2

--------------------------------------------------------------------------------